Table 1 Participant characteristics
Participants (n = 20) | |
|---|---|
Age, mean (SD), y | 62.9 (10.2) |
Sex, n (%) | |
Male | 12 (60.0) |
Female | 8 (40.0) |
Race/Ethnicity, n (%) | |
White/Hispanic or Latino | 2 (10.0) |
White/Not Hispanic or Latino | 18 (90.0) |
IRLS total score at baseline, mean (SD) | 9.8 (8.5) |
Duration of RLS symptoms, mean (SD), y | 31.1 (14.1) |
Number of prior RLS medications, mean (SD) | 3.2 (1.6) |
Prior RLS medications, n (%) | |
Dopamine agonist | 19 (95.0) |
Alpha-2-delta ligand | 12 (60.0) |
Benzodiazepine | 4 (20.0) |
Opioid | 2 (10.0) |
Duration of opioid treatment for RLS, mean (SD), y | 8.0 (4.6) |
Baseline opioid dose, mean (SD), MME | 39.0 (15.6) |
Current RLS medications, n (%) | |
Methadone | 18 (90.0) |
Oxycodone | 2 (10.0) |
Dopamine agonist | 4 (20.0) |
Alpha-2-delta ligand | 3 (15.0) |